J&J sues Samsung Bioepis over contract breach for Stelara biosimilar [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which the drugmaker declined to identify. The company, along with partner Sandoz, said earlier on Monday that its biosimilar Pyzchiva is now available in the United States. J&J over the past two years has signed settlement agreements with several companies to delay the U.S. launches of Stelara, its top-selling drug since 2019. Close copies of Stelara launched in Europe, Canada and a few other markets last year and at least six close copies of Stelara are expected to launch in the U.S. this year. Teva Pharmaceuticals and Alvotech last Friday launched Selarsdi, a biosimilar to Stelara. The U.S. Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only after April 30, when the exclusive rights for Amgen's Wezlana expire. Pyzchiva is approved to treat moderate to severe plaque ps
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- This International Pharma Stock Just Hit 5-Year Highs [Yahoo! Finance]Yahoo! Finance
- S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive [Yahoo! Finance]Yahoo! Finance
- S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to PositiveGlobeNewswire
- Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 11/5/25 - Beat
TEVA
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/12/25 - Form 144
- TEVA's page on the SEC website